Cell Therapy and Biologic Medicinal Products
sqm of manufacturing and quality control facilities.
Cell Therapy Programs
Our experience with adult mesenchymal stem cells
Most basal mesenchymal stem cells die immediately after transplantation, limiting their therapeutic potential.
During the acute phase of the disease, tissue is exposed to a highly damaging environment, with persistent oxidative stress and pathological inflammation.
HC016 Cells
- New allogeneic adult mesenchymal stem cell technology for oxidative stress-mediated pathologies.
- Cells obtained from adipose tissue under a process patented by Histocell.
- Higher survival and bioactivity than basal mesenchymal cells in oxidative and inflammatory environments: proven increase in therapeutic efficacy.
Indications:
- Pathologies associated with a highly oxidative microenvironment are particularly suitable targets for HC016 cells.
- Treatment of diseases with a relevant inflammatory component.
Enhanced therapeutic effect of mesenchymal stem cells (HC016), increasing anti-inflammatory and antioxidant response.
- HC016 is configured to act in pro-inflammatory environments and aims to protect damaged host tissues.
- HC016 cells activate self-defence pathways against oxidative stress and inflammatory environments.
ASC cell-based therapeutic programmes
Treatment of acute spinal cord injuries.
Mesenchymal stem cells from adipose tissue patented by Histocell.
Phase I-IIa completed with 20 patients treated.
Treatment of acute respiratory distress syndrome (ARDS).
Mesenchymal stem cells from adipose tissue patented by Histocell.
Phase I-IIa completed with 26 patients treated.
Bone regeneration in non-union fractures, infections, resections, trauma.
Pre-differentiated ASCs.
Phase IIa completed with 12 patients with highly positive safety and efficacy results.